Regeneron and BioNTech Partner on Immunotherapy Combo for Melanoma

Source: BioSpace, August 2020

Although Mainz, Germany-based BioNTech is getting a lot of attention because of its partnership with Pfizer on a COVID-19 vaccine, the mRNA company has a broader approach than just infectious diseases. Now, Regeneron Pharmaceuticals and BioNTech have inked a strategic collaboration to combine BioNTech’s BNT111 FixVac product candidate and Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab) for the treatment of melanoma.

Regeneron and BioNTech plan to run a randomized Phase II trial in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma. Melanoma is the deadliest form of skin cancer, taking the lives of more than 63,000 people around the world each year.

READ THE ORIGINAL FULL ARTICLE